SanBio Company Limited (4592.T)
JPY 2255.0
(5.37%)
JPY 2255.0
(5.37%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 397 Million JPY | -40.3% |
| 2022 | 665 Million JPY | -66.96% |
| 2021 | 2.01 Billion JPY | -20.3% |
| 2020 | 2.52 Billion JPY | -27.86% |
| 2019 | 3.5 Billion JPY | -12.5% |
| 2018 | 4 Billion JPY | 79.1% |
| 2017 | 2.23 Billion JPY | 94.2% |
| 2016 | 1.15 Billion JPY | 283.34% |
| 2015 | 300 Million JPY | -72.73% |
| 2014 | 1.1 Billion JPY | 0.0% |
| 2013 | - JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 330 Million JPY | -16.88% |
| 2024 Q2 | 263 Million JPY | -20.3% |
| 2023 Q2 | 531 Million JPY | -11.2% |
| 2023 Q4 | 397 Million JPY | -14.44% |
| 2023 FY | 397 Million JPY | -40.3% |
| 2023 Q1 | 598 Million JPY | -10.08% |
| 2023 Q3 | 464 Million JPY | -12.62% |
| 2022 Q4 | 665 Million JPY | -9.15% |
| 2022 Q3 | 732 Million JPY | -57.57% |
| 2022 FY | 665 Million JPY | -66.96% |
| 2022 Q2 | 1.72 Billion JPY | -7.69% |
| 2022 Q1 | 1.86 Billion JPY | -7.14% |
| 2021 FY | 2.01 Billion JPY | -20.3% |
| 2021 Q4 | 2.01 Billion JPY | -12.5% |
| 2021 Q2 | 2.3 Billion JPY | 0.0% |
| 2021 Q1 | 2.3 Billion JPY | -8.91% |
| 2021 Q3 | 2.3 Billion JPY | 0.0% |
| 2020 Q2 | 1.9 Billion JPY | -45.71% |
| 2020 FY | 2.52 Billion JPY | -27.86% |
| 2020 Q4 | 2.52 Billion JPY | 32.89% |
| 2020 Q3 | 1.9 Billion JPY | 0.0% |
| 2020 Q1 | 3.5 Billion JPY | 0.0% |
| 2019 FY | 3.5 Billion JPY | -12.5% |
| 2019 Q3 | 4 Billion JPY | 0.0% |
| 2019 Q4 | 3.5 Billion JPY | -12.5% |
| 2019 Q2 | 4 Billion JPY | 0.0% |
| 2019 Q1 | 4 Billion JPY | 0.0% |
| 2018 FY | 4 Billion JPY | 79.1% |
| 2018 Q4 | 4 Billion JPY | 48.15% |
| 2018 Q3 | 2.7 Billion JPY | 0.0% |
| 2018 Q2 | 2.7 Billion JPY | -0.62% |
| 2018 Q1 | 2.71 Billion JPY | 21.64% |
| 2017 Q1 | 2.28 Billion JPY | 98.55% |
| 2017 FY | 2.23 Billion JPY | 94.2% |
| 2017 Q4 | 2.23 Billion JPY | -0.74% |
| 2017 Q3 | 2.25 Billion JPY | -0.73% |
| 2017 Q2 | 2.26 Billion JPY | -0.73% |
| 2016 Q2 | 300 Million JPY | 0.0% |
| 2016 FY | 1.15 Billion JPY | 283.34% |
| 2016 Q3 | 1.16 Billion JPY | 288.89% |
| 2016 Q1 | 300 Million JPY | 0.0% |
| 2016 Q4 | 1.15 Billion JPY | -1.43% |
| 2015 Q2 | 1.1 Billion JPY | 0.0% |
| 2015 Q1 | 1.1 Billion JPY | 0.0% |
| 2015 Q4 | 300 Million JPY | -72.73% |
| 2015 FY | 300 Million JPY | -72.73% |
| 2015 Q3 | 1.1 Billion JPY | 0.0% |
| 2014 FY | 1.1 Billion JPY | 0.0% |
| 2014 Q4 | 1.1 Billion JPY | 0.0% |
| 2013 FY | - JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 767.03 Million JPY | 48.242% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 2 Billion JPY | 80.15% |
| Linical Co., Ltd. | 1.49 Billion JPY | 73.532% |
| Trans Genic Inc. | 1.32 Billion JPY | 70.085% |
| MEDINET Co., Ltd. | 781 Thousand JPY | -50732.266% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.34 Billion JPY | 83.085% |
| AnGes, Inc. | 214.94 Million JPY | -84.695% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | -271.552% |
| Nxera Pharma Co., Ltd. | 63.21 Billion JPY | 99.372% |
| Immuno-Biological Laboratories Co., Ltd. | 84.56 Million JPY | -369.484% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 64.199% |
| Carna Biosciences, Inc. | 28.4 Million JPY | -1297.789% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 875.59 Million JPY | 54.66% |
| RaQualia Pharma Inc. | 39.05 Million JPY | -916.645% |
| Chiome Bioscience Inc. | - JPY | -Infinity% |
| Kidswell Bio Corporation | 1.83 Billion JPY | 78.4% |
| PeptiDream Inc. | 19.63 Billion JPY | 97.978% |
| Oncolys BioPharma Inc. | 161.1 Million JPY | -146.431% |
| Ribomic Inc. | - JPY | -Infinity% |
| Healios K.K. | 450 Million JPY | 11.778% |
| BrightPath Biotherapeutics Co., Ltd. | - JPY | -Infinity% |
| Kubota Pharmaceutical Holdings Co., Ltd. | - JPY | -Infinity% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 77.29 Million JPY | -413.643% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 773.29 Million JPY | 48.661% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 788 Million JPY | 49.619% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 491.35 Million JPY | 19.202% |
| StemCell Institute Inc. | 6.67 Million JPY | -5846.675% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 143.75 Million JPY | -176.174% |